BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway

Glioblastoma is the most common type of malignant intracranial tumor in adults. Temozolomide (TMZ), as the first-line chemotherapy agent used in patients with glioblastoma, has demonstrated different effects in patients due to the expression of O6-methylguanine-DNA methyltransferase (MGMT) which is...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mao, Liang, Ruo Fei, Wang, Xiang, Mao, Qing, Liu, Yan Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680702/
https://www.ncbi.nlm.nih.gov/pubmed/29151909
http://dx.doi.org/10.3892/ol.2017.7034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680702/
https://www.ncbi.nlm.nih.gov/pubmed/29151909
http://dx.doi.org/10.3892/ol.2017.7034

Ejemplares similares